Archives: Agenda

The clinical trial monitoring function has been transforming as sponsor companies move beyond traditional monitoring to accommodate risk-based, centralized, and AI-enabled approaches. This session explores specific organizational changes that have been made to support this transformation and its impact workforce capacity, timelines and efficiency. Attendees will gain practical insights into building monitoring models that enhance study quality, operational efficiency, and regulatory readiness. 

• Baseline metabolic heterogeneity can be measured and may contribute to differences in treatment response.
• A single blood sample provides a quantitative profile of six key redox metabolites.
• Redox profiling can support patient stratification and monitoring of treatment-related metabolic changes.
• The analysis can be integrated into clinical trials using a small aliquot of routinely collected blood, with centralized analysis and minimal impact on existing workflows.

• Operational Strain: Traditional, manual audit trail reviews across siloed clinical systems drain clinical operations resources, delay study close-out, and increase regulatory compliance risks.
• Unified Ingestion: Workflow automation continuously ingests disparate digital logs from EDC, eCOA, and IRT systems into a single, standardized operational layer.
• Intelligent Traceability: Autonomous AI agents map complex patient data journeys across the digital network, automatically flagging data anomalies and out-of-sequence transactions.
• Business Impact: Shifting from reactive sampling to automated, comprehensive oversight slashes inspection-readiness timelines, optimizes trial oversight, and guarantees ironclad data integrity.

• The evolution of AI in clinical trial operations and the problems it can solve
• Choosing safe, transparent and fit-for-purpose AI
• Moving from fragmented tools to unified, traceable trial infrastructure
• Real-world impact, adoption and ROI through case studies